Targeting apoptosis in acute myeloid leukaemia

Autor: Amine Belhabri, Marie Castets, Philippe A. Cassier, Norbert Vey
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
BCL2
Myeloid
Genetic enhancement
medicine.medical_treatment
Antineoplastic Agents
X-Linked Inhibitor of Apoptosis Protein
Hematopoietic stem cell transplantation
Review
Inhibitor of Apoptosis Proteins
03 medical and health sciences
0302 clinical medicine
XIAP
MDM2
Internal medicine
hemic and lymphatic diseases
medicine
Humans
acute myeloid leukaemia
Molecular Targeted Therapy
business.industry
Hematopoietic Stem Cell Transplantation
apoptosis
Proto-Oncogene Proteins c-mdm2
medicine.disease
Transplantation
Clinical trial
Haematopoiesis
Leukemia
Leukemia
Myeloid
Acute
Receptors
TNF-Related Apoptosis-Inducing Ligand
030104 developmental biology
medicine.anatomical_structure
Proto-Oncogene Proteins c-bcl-2
030220 oncology & carcinogenesis
Stem cell
Tumor Suppressor Protein p53
business
Zdroj: British Journal of Cancer
ISSN: 1532-1827
Popis: Acute myeloid leukaemia (AML) is a molecularly and clinically heterogeneous disease, and its incidence is increasing as the populations in Western countries age. Despite major advances in understanding the genetic landscape of AML and its impact on the biology of the disease, standard therapy has not changed significantly in the last three decades. Allogeneic haematopoietic stem cell transplantation remains the best chance for cure, but can only be offered to a minority of younger fit patients. Molecularly targeted drugs aiming at restoring apoptosis in leukaemic cells have shown encouraging activity in early clinical trials and some of these drugs are currently being evaluated in randomised controlled trials. In this review, we discuss the current development of drugs designed to trigger cell death in AML.
Databáze: OpenAIRE
Externí odkaz: